358 related articles for article (PubMed ID: 31465739)
21. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
22. Uncommon pretibial bilateral manifestation of Hidradenitis suppurativa (Hurley III) after discontinuation of systemic treatment with adalimumab: a serious reason to prefer surgery as a primary approach?
Tchernev G; Temelkova I; Wollina U
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e449-e451. PubMed ID: 31273867
[No Abstract] [Full Text] [Related]
23. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
Theut Riis P; Thorlacius LR; Jemec GB
Expert Opin Investig Drugs; 2018 Jan; 27(1):43-53. PubMed ID: 29188733
[TBL] [Abstract][Full Text] [Related]
24. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
[TBL] [Abstract][Full Text] [Related]
25. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
Argyropoulou M; Kanni T; Kyprianou M; Melachroinopoulos N; Giamarellos-Bourboulis EJ
Br J Dermatol; 2019 May; 180(5):1161-1168. PubMed ID: 30192377
[TBL] [Abstract][Full Text] [Related]
26. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
[No Abstract] [Full Text] [Related]
28. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
Ingram JR; Burton T
Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
[No Abstract] [Full Text] [Related]
29. Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression.
Cao Y; Harvey BP; Hong F; Ruzek M; Wang J; Murphy ER; Kaymakcalan Z
J Invest Dermatol; 2021 Nov; 141(11):2730-2740.e9. PubMed ID: 33965402
[TBL] [Abstract][Full Text] [Related]
30. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
31. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Harde V; Mrowietz U
J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
[TBL] [Abstract][Full Text] [Related]
32. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
[TBL] [Abstract][Full Text] [Related]
34. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM
Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
Cline A; Pichardo RO
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
[TBL] [Abstract][Full Text] [Related]
36. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
37. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
Clin Exp Dermatol; 2021 Mar; 46(2):306-313. PubMed ID: 32931599
[TBL] [Abstract][Full Text] [Related]
38. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
Vekic DA; Frew JW
Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
[No Abstract] [Full Text] [Related]
39. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
Diamantova D; Lomickova I; Cetkovska P
Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
[TBL] [Abstract][Full Text] [Related]
40. Adalimumab (Humira
Gupta AK; Cernea M; Abramovits W; Vincent KD
Skinmed; 2016; 14(4):291-294. PubMed ID: 27784520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
